Syrosingopine

Syrosingopine
Clinical data
ATC code	C02LA09 (WHO) (combination with diuretics);
Identifiers
	IUPAC name Methyl (3β,16β,17α,18β,20α)-18-({4-[(Ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl}oxy)-11,17-dimethoxyyohimban-16-carboxylate;
CAS Number	84-36-6;
PubChem CID	6769;
ChemSpider	6511;
UNII	PPG46JF0EG;
KEGG	D01659;
Chemical and physical data
Formula	C35H42N2O11
Molar mass	666.724 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)Oc1c(cc(cc1OC)C(=O)O[C@@H]2C[C@@H]3CN4CCc5c6ccc(cc6[nH]c5[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC)OC)OC;
	InChI InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1; Key:ZCDNRPPFBQDQHR-SSYATKPKSA-N;

Syrosingopine is a drug, derived from reserpine. It is used (since about 1960) to treat hypertension.[1][2]

Research

A combination of the diabetes drug metformin and syrosingopine killed tumor cells in blood samples from leukemia patients, while it did not damage blood cells in samples from healthy patients. The combination of metformin and syrosingopine also reduced or eliminated tumors in mice with malignant liver cancer.[3] The drugs interfere with the cancer cells' glucose (i.e. energy) supply and utilization. Cancer cells have much higher energy requirements than normal cells, making them vulnerable when there is a reduction in the available energy supply. Syrosingopine inhibits the degradation of sugars within the cells.[4]

References

Shelburne, P. F.; Orgain, E. S. (1963). "Comparison of syrosingopine and reserpine in the treatment of ambulatory hypertensive patients". The American Journal of the Medical Sciences. 245: 304–10. PMID 13977067.
Bartels, Carl C. (1959). "Syrosingopine — A New Rauwolfia Preparation". New England Journal of Medicine. 261 (16): 785. doi:10.1056/NEJM195910152611603.
Benjamin, Don (23 Dec 2016). "Syrosingopine sensitizes cancer cells to killing by metformin". Science Advances. 2 (12). PMC 5182053. PMID 28028542. Retrieved 18 January 2017. We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells.
"Treating cancer with drugs for diabetes and hypertension". Science Daily. December 27, 2016. Retrieved 18 January 2017. The antihypertensive drug syrosingopine potentiates the anti-cancer efficacy of metformin.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Sh1963-1] Shelburne, P. F.; Orgain, E. S. (1963). "Comparison of syrosingopine and reserpine in the treatment of ambulatory hypertensive patients". The American Journal of the Medical Sciences. 245: 304–10. PMID 13977067.

[2] Bartels, Carl C. (1959). "Syrosingopine — A New Rauwolfia Preparation". New England Journal of Medicine. 261 (16): 785. doi:10.1056/NEJM195910152611603.

[3] Benjamin, Don (23 Dec 2016). "Syrosingopine sensitizes cancer cells to killing by metformin". Science Advances. 2 (12). PMC 5182053. PMID 28028542. Retrieved 18 January 2017. We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells.

[4] "Treating cancer with drugs for diabetes and hypertension". Science Daily. December 27, 2016. Retrieved 18 January 2017. The antihypertensive drug syrosingopine potentiates the anti-cancer efficacy of metformin.